Top 10 Medicines by Reported Q2 2024 Sales
Unpacking Q2 2024 Results: Sales of 10 Major Medicines
The second-quarter 2024 results show how sales growth at Keytruda, Mounjaro and Skyrizi compares with the decline in Humira. Below, we examine the reported sales and clinical developments behind these medicines.
The comparison uses the companies’ reported product revenues for April–June 2024 and the same quarter in 2023. Ozempic’s Danish-krone sales are converted using each quarter’s average daily ECB exchange rate; Dupixent uses Regeneron’s reported dollar value of global customer sales. Eliquis is shown at BMS-reported revenue—$3.416 billion in Q2 2024 and $3.204 billion in Q2 2023—which includes alliance revenue in certain markets. Pfizer’s Eliquis revenue is not added because the partners’ reported amounts overlap. These are the ten largest medicines by company-reported Q2 2024 revenue. Boehringer Ingelheim does not report quarterly Jardiance sales, so Jardiance cannot be ranked. BMS alliance accounting
Keytruda: 45% of Merck's Quarterly Sales
Merck reported Q2 2024 Keytruda sales of $7.270 billion, up 16% from $6.271 billion a year earlier. That represented 45.1% of Merck's $16.112 billion in total quarterly sales. On June 17, 2024, the FDA approved pembrolizumab with carboplatin and paclitaxel, followed by pembrolizumab alone, for adults with primary advanced or recurrent endometrial carcinoma. Merck Q2 results; FDA approval
This concentration makes revenue beyond Keytruda important to Merck's longer-term growth. Merck's published patent schedule lists Keytruda's compound patent expiry in 2028 in the U.S. and 2031 in major European markets. Those patent dates do not establish the exact timing or size of future biosimilar sales erosion. Merck patent schedule
The GLP-1 Showdown
Eli Lilly reported Q2 2024 Mounjaro sales of $3.091 billion, more than three times the $979.7 million reported in Q2 2023. Novo Nordisk reported Ozempic sales of DKK 28.875 billion. At the quarter's average ECB daily USD-per-DKK exchange rate, Ozempic sales were approximately $4.168 billion, putting Mounjaro at about 74% of that amount. This is a revenue comparison, not a measure of prescription or patient market share. Lilly Q2 results; Novo Nordisk Q2 sales data; ECB exchange rates
In SURPASS-2, adults with type 2 diabetes receiving tirzepatide 5, 10 or 15 mg had greater mean weight reductions at 40 weeks than those receiving semaglutide 1 mg. This finding applies to the doses and population studied; it does not establish superiority over every semaglutide regimen. Lilly also reported manufacturing expansion and improved supply in Q2, but those developments do not by themselves establish future market-share gains. SURPASS-2 trial publication; Lilly Q2 supply update
AbbVie: Navigating Post-Humira Landscape
Skyrizi and Rinvoq helped offset Humira's sales decline. Q2 2024 Skyrizi sales were $2.727 billion, an increase of $844 million from Q2 2023. Humira sales fell by $1.198 billion to $2.814 billion, so Skyrizi alone offset about 70% of that decline. Rinvoq added another $512 million in growth, reaching $1.430 billion. Together, Skyrizi and Rinvoq's $1.356 billion increase exceeded Humira's decline by $158 million. AbbVie Q2 2024 results; AbbVie Q2 2023 results
Johnson & Johnson: Preparing for Competition
Johnson & Johnson reported Q2 2024 Stelara sales of $2.885 billion, compared with $2.797 billion a year earlier. The company was preparing for U.S. Stelara biosimilar competition in 2025 while developing Tremfya in Crohn's disease. In the pooled GALAXI 2 and 3 results presented in May 2024, both Tremfya maintenance regimens showed statistically significant advantages over Stelara on endoscopic response and remission at week 48. Clinical remission alone was not significantly different: 70.3% and 65.4% for the Tremfya regimens versus 62.9% for Stelara (p=0.058 and p=0.512). These results support specific endoscopic benefits rather than an unqualified claim of clinical superiority. GALAXI 2 and 3 results; J&J Q2 sales; J&J 2023 outlook
Conclusion
Q2 2024 highlights different commercial challenges: Merck's concentration in Keytruda, rapid Mounjaro growth, and AbbVie's shift from Humira toward Skyrizi and Rinvoq. Sales figures describe commercial performance, while clinical comparisons require the specific trial population, dose and endpoint. Neither establishes how these products will perform in future quarters.